Erbitux Articles
News briefs from Threshold, Merck KGaA and GSK
18 September 2012
News briefs from Merck KGaA and Sanofi
5 July 2012
Added indication for Bristol-Myers’ Erbitux approved by FDA
8 November 2011
UK’s NICE negative draft guidance for metastatic colorectal cancer drugs Erbitux, Avastin and Vectibix
6 September 2011
Erbitux and Gilenya added to Australia’s PBS listing
2 September 2011
Merck KGaA strengthens research cooperation with Israel; files for Erbitux indication extension
31 March 2011
Merck Serono says Erbitux long-term survival benefit for mCRC patients confirmed with FOLFOX
19 January 2011
Strong cancer drug results presented by Roche, Sanofi-Aventis, Merck KGaA, Amgen and Eisai at ESMO Congress
12 October 2010
Medicines Australia agreement to reduce Rx drug prices; Merck Serono’s Erbitux funding under PBS recommended
23 August 2010
Multinational drugmakers’ sales will represent 92% of Mexico's NSCLC cancer drug Market in 2014
1 August 2010
Bristol-Myers Squibb forecasts large jump in 2010 profit to range of $1.94 to $2.04 per share
29 January 2010
Idera gets $4.3 million clinical milestone under its cancer drug deal with Merck KGaA
20 January 2010
Ambit sells rights for FLT3 Kinase inhibitors to Japan’s Astellas for up to $390 million
18 December 2009
Celgene buys rival Gloucester for $640 million, gaining rights to Istodax; Allos defends price of Folotyn
8 December 2009
Merck KGaA's Erbitux boosts colorectal cancer survival rate
27 November 2009
Merck KGaA gets second CHMP rejection for Erbitux in Advanced Non-Small Cell Lung Cancer
20 November 2009
Bristol-Myers Squibb decides to split off Mead Johnson nutritional unit to concentrate on biopharma
17 November 2009
Targeted agents will drive gastric cancer drug market to nearly $1.5 billion in 2018
5 November 2009
Bristol-Myers sees 64% leap in 3rd quarter 2009 ongoing earnings
23 October 2009
Eli Lilly 3rd quarter 2009 beats forecasts, raises guidance
22 October 2009
ECCO/ESMO: new data show Merck Serono ’s Erbitux extends survival in colorectal and lung cancers
28 September 2009
Merck KGaA hit by disappointing Erbitux results from COIN study
24 September 2009
Biosimilars of Rituxan, MabThera, Herceptin and Erbitux will erode $8.2 billion in US and European sales in 2018
17 September 2009
UK’s NICE recommends Merck KGaA’s Erbitux cetuximab for the first-line treatment of metastatic colorectal cancer
26 August 2009
Amgen scores with cancer drug, says Zacks analysts
10 August 2009
UK's NICE OKs Merck KGaA's Erbitux for mCRC
2 June 2009
Lilly's 1st-qtr profit jumps 23.6% to $1.31B
29 April 2009
B-MS' 1st qtr hit by tax and legal costs
29 April 2009
Merck KGaA's 1st-qtr profit tumbles 76.3% to 56.7M euros on lower liquid crystal sales
27 April 2009
Erbitux cuts mCRC progression risk 32%
7 April 2009
NexGen founder's patent improves chemo
30 March 2009
Merck Serono expands cilengitide program
23 March 2009
FDA asks for PK study before approving Erbitux sBLA
9 March 2009
Idera receives $3.8M fee from Merck KGaA
9 February 2009
Biothera expands Imprime/Erbitux combo trial
9 February 2009
Ph II wild-type KRAS data support Erbitux
19 January 2009
Erbitux has almost double KRAS response in trial
12 January 2009
FDA may insist on KRAS tests for cancer patients
22 December 2008
Merck Serono extends Erbitux indication
15 December 2008
Stock Commentary - Europe - week to Dec 1, 2008
8 December 2008
Merck KGaA gets EU extension for Erbitux
8 December 2008
NCCN gets $1.5M grant from B-MS/ImClone
1 December 2008
German Cartel Office clears Lilly's buy of ImClone
24 November 2008
Erbitux extends NSCLC survival up to 15 months
24 November 2008
FDA accepts B-MS/ImClone's Erbitux sBLA
10 November 2008
ImClone/B-MS' Erbitux launched in Canada
3 November 2008
Bristol-Myers Squibb's 3rd-qtr 2008 profit triples due to big gain from $4.1B sales of ConvaTec
3 November 2008
Merck Serono's Erbitux nominated for Prix Galien
20 October 2008
Idera reports first data from carcinoma trial
6 October 2008
UPDATE: B-MS goes to ImClone shareholders with slightly higher bid, which Icahn rejects
29 September 2008
Benefits of Erbitux in WT-KRAS mCRC tumors highlighted at ESMO
22 September 2008
Erbitux increases overall survival in SCCHN
15 September 2008
B-MS will not raise bid for ImClone
15 September 2008
ImClone offers more data from Erbitux trial
8 September 2008
ImClone R&D offsets Erbitux sales in 2nd qtr
4 August 2008
Merck Serono to grow Japanese business
4 August 2008
B-MS' profit accelerates on good exchange rate
4 August 2008
Merck KGaA 's Erbitux gets broader use in mCRC
28 July 2008
Lab21 ramps up KRAS and EGFR testing capacity
28 July 2008
Roche
7 July 2008
DxS launches K-RAS test in Australia
7 July 2008
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
